Beaumont Financial Advisors LLC Sells 624 Shares of Bristol-Myers Squibb (NYSE:BMY)

Beaumont Financial Advisors LLC lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 5.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,625 shares of the biopharmaceutical company’s stock after selling 624 shares during the quarter. Beaumont Financial Advisors LLC’s holdings in Bristol-Myers Squibb were worth $601,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of BMY. GSA Capital Partners LLP lifted its position in shares of Bristol-Myers Squibb by 4.1% in the 4th quarter. GSA Capital Partners LLP now owns 66,286 shares of the biopharmaceutical company’s stock worth $3,401,000 after acquiring an additional 2,600 shares during the period. Optimist Retirement Group LLC bought a new position in Bristol-Myers Squibb in the fourth quarter worth $410,000. Oarsman Capital Inc. boosted its stake in Bristol-Myers Squibb by 2.0% during the fourth quarter. Oarsman Capital Inc. now owns 28,021 shares of the biopharmaceutical company’s stock worth $1,438,000 after buying an additional 554 shares in the last quarter. FIL Ltd increased its holdings in Bristol-Myers Squibb by 1.4% in the 4th quarter. FIL Ltd now owns 7,681,165 shares of the biopharmaceutical company’s stock valued at $394,121,000 after buying an additional 107,009 shares during the period. Finally, Voisard Asset Management Group Inc. acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $73,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on BMY. Barclays upped their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. Jefferies Financial Group increased their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research report on Wednesday, August 28th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and set a $48.00 price objective on shares of Bristol-Myers Squibb in a research note on Monday, September 23rd. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $53.00.

Bristol-Myers Squibb Stock Down 0.4 %

Shares of BMY opened at $52.19 on Friday. The firm has a market capitalization of $105.79 billion, a price-to-earnings ratio of -16.84, a PEG ratio of 13.75 and a beta of 0.46. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $57.65. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16. The business’s fifty day moving average price is $49.75 and its two-hundred day moving average price is $46.43.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.43. The business had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.75 earnings per share. On average, analysts predict that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.60%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.